Numerous studies showed that the PI3K/AKT/mTOR signaling pathway activates upstream receptors (EGFR and PDGF) and is mutated in a variety of cancers, including breast cancer, gastric cancer, and NSCLC [43–45]. This evidence concerns the gene AKT1 and breast carcinoma.